Clinical Trial Data Presentation, Full-Year Guidance, and Presentations at Conferences - Research Report on Haemonetics, Centene, Endologix, Natus, and Stemline

NEW YORK, November 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Haemonetics Corporation (NYSE: HAE), Centene Corporation (NYSE: CNC), Endologix, Inc. (NASDAQ: ELGX), Natus Medical Incorporated (NASDAQ: BABY), and Stemline Therapeutics, Inc. (NASDAQ: STML). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Haemonetics Corporation Research Report

On November 13, 2013, Haemonetics Corporation (Haemonetics) announced that its CFO and EVP for Business Development, Chris Lindop will participate at the Jefferies 2013 Global Healthcare Conference. According to the Company, the event will be held on November 21, 2013 at 2:20 p.m. GMT or 9:20 a.m. ET, in London, England. Haemonetics further informed that interested parties may access a live webcast of Mr. Lindop's presentation via the Company website. The Full Research Report on Haemonetics Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7c61_HAE

--

Centene Corporation Research Report  

On November 7, 2013, Centene Corporation (Centene) announced that it intends to release its 2014 financial guidance on Friday, December 13, 2013 at approximately 6:00 a.m. ET. According to the Company, it will also host an investor meeting, including a question-and-answer session to discuss the details of its guidance, between 8:30 a.m. to 11:00 a.m. ET. Centene further informed that it's Chairman and CEO, Michael F. Neidorff, and Executive Vice President, CFO, and Treasurer, William N. Scheffel, will host the investor meeting. The Full Research Report on Centene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e85d_CNC

--

Endologix, Inc. Research Report  

On November 12, 2013, Endologix, Inc. (Endologix) announced that it will host its 2013 investor meeting on November 20, 2013, from 5:30 p.m. to 7:00 p.m. at the New York Hilton Midtown. According to the Company, the event will include a Company update, presentations from prominent physicians and a question and answer session with the physicians and Endologix management. Besides, a live audio webcast of the same can be accessed by interested parties at the investor relations section of Endologix's website. The Full Research Report on Endologix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/2f8d_ELGX

--

Natus Medical Incorporated Research Report

On November 14, 2013, Natus Medical Incorporated (Natus) announced that its President and CEO, Jim Hawkins will make a presentation at the 25^th Annual Piper Jaffray Healthcare Conference. The Company informed that the conference will be held between December 3-4, 2013 at the New York Palace Hotel, New York, NY. According to the Company, Hawkins is scheduled to present on December 3, 2013 at 2:30 p.m. ET or 11:30 a.m. PT and investors may listen to the live webcast of the same via the "Investor" section of the Company's web site. The Full Research Report on Natus Medical Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/03ac_BABY

--

Stemline Therapeutics, Inc. Research Report  

On November 14, 2013, Stemline Therapeutics, Inc. (Stemline) announced five presentations at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held at the Ernest N. Moral Convention Center in New Orleans, LA, from December 7-10, 2013. The Company informed that investigators will present the following four abstracts on SL-401, a novel targeted therapy directed to the Interleukin-3 Receptor on cancer stem cells (CSCs) and Tumor Bulk, in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), via poster presentation - an update on the robust clinical activity; Preclinical Studies: Potent Activity in BPDCN Cell Lines, Primary Tumor, and in an In Vivo Model; Possesses Preclinical Cytotoxic Activity against Chronic Eosinophilic Leukemia; and Inhibits Plasmacytoid Dendritic Cell (pDC)-induced Myeloma Cell Growth and Overcomes Drug Resistance. Further, investigators will also present preclinical data on Leukemia Stem Cell Marker CD123 (IL-3R alpha) Predicts Minimal Residual Disease and Relapse, Providing a Valid Target for SL-101 in Acute Myeloid Leukemia with FLT3-ITD Mutations via an oral presentation. "The results being presented at ASH, including a new CR, continue to validate SL-401's robust clinical activity in patients with BPDCN, as well as its clinical potential in multiple other IL-3R expressing cancers based on its potent activity in experimental models," said Eric K. Rowinsky, M.D., Chief Medical Officer and Head of Research and Development at Stemline. "It is gratifying to observe robust responsiveness in previously treated patients with BPDCN and AML, especially after receiving only a single cycle of SL-401." The Full Research Report on Stemline Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5155_STML

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner